SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Rajesh Pahwa, Caroline M. Tanner, Robert A. Hauser, Kapil Sethi, Stuart Isaacson, Daniel Truong, Lynn Struck, April E. Ruby, Natalie L. McClure, Gregory T. Went, Mary Jean Stempien, Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study), Movement Disorders, 2015, 30, 5
  2. 2
    William R. Lenderking, Sally Mannix, Jennifer Petrillo, Christopher Kenney, Amanda Landrian, Anette-Eleonore Schrag, Assessment of Parkinson’s disease levodopa-induced dyskinesia: a qualitative research study, Quality of Life Research, 2015,

    CrossRef

  3. You have free access to this content3
    Esther Cubo, Christopher G. Goetz, Glenn T. Stebbins, Nancy R. LaPelle, Barbara C. Tilley, Lu Wang, Sheng Luo, Independent Spanish Validation of the Unified Dyskinesia Rating Scale, Movement Disorders Clinical Practice, 2014, 1, 3
  4. 4
    Oliver Riedel, Jens Klotsche, Hans-Ulrich Wittchen, Motor impairment, depression, dementia: Which forms the impression of disease severity in Parkinson's disease?, Parkinsonism & Related Disorders, 2014, 20, 12, 1365

    CrossRef

  5. 5
    Eva Schaeffer, Andrea Pilotto, Daniela Berg, Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease, CNS Drugs, 2014, 28, 12, 1155

    CrossRef

  6. 6
    Olivier Rascol, Susan Fox, Fabrizio Gasparini, Christopher Kenney, Thérèse Di Paolo, Baltazar Gomez-Mancilla, Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias, Parkinsonism & Related Disorders, 2014, 20, 9, 947

    CrossRef